1
One Sample
A simple at-home finger-prick collected over 5 days. No clinic visits, no fasting, friction-free scaling.
Investor Relations
Building the infrastructure for preventive medicine.
We turn a single finger-prick into a continuously learning virtual twin. A dual-engine model monetizing consumer wellness today to build the clinical multi-cancer detection AI of tomorrow.
- Clinical pilot, Cleveland Clinic Abu Dhabi
- Microsoft for Startups
- $5M raised
Our Core Asset
Your blood. 30,000 biomarkers.
Your blood. 30,000 biomarkers.
Virtual twin.
Standard blood tests read 20 to 30 parameters. BioTwin reads over 30,000 biomarker signals from a single finger-prick using mass spectrometry, creating an unparalleled dataset for predictive AI.
2
30,000 Signals
High-resolution mass spectrometry captures a complete metabolic signature, not just a targeted checklist.
3
3 Programs
Raw data is organized into actionable health programs: Healthspan and Longevity, Elite Human Optimization, and Weight Management.
4
Virtual Twin
A living mathematical model that learns retroactively. When our research team adds a new analysis, the twin updates without a new kit.
Go-to-market strategy
Consumer today.
Consumer today.
Clinical tomorrow.
The data required to train clinical AI for complex diseases is vast and expensive to acquire. BioTwin solves this cold-start problem through a self-funding data flywheel.
-
TwinMe (Consumer): We deliver immediate value through 3 commercial wellness programmes (Longevity, Elite Optimization, Weight) generating immediate revenue.
-
BioTwin (Clinical): Every anonymized finger-prick continuously expands our multi-omics database, directly training our predictive models for oncology and chronic diseases.
N=1
Personalized
Medicine
Medicine
"By mapping individual trajectories rather than population averages, we can detect minute biological deviations before they manifest as clinical symptoms."
Scientific Pipeline
Active clinical traction.
Our virtual twin technology is already deployed in real-world clinical environments.
Clinical pilot, active
Abu Dhabi, UAE Cleveland Clinic Abu Dhabi
BioTwin's first clinical pilot delivers results today through partner physicians at Cleveland Clinic Abu Dhabi. The programme is under the regulatory framework of the United Arab Emirates.
Current screening: Breast cancer · Colorectal cancer
Performance: Current models demonstrate 0.78 sensitivity across 6 cancer types using multi-omics integration.
Research in progress
Global Broader clinical pipeline
Beyond the UAE pilot, BioTwin runs active research programs globally, supported by over 50 published studies validating our biomarker signatures.
- Oncology: Lung, Pancreas, Prostate, Ovarian
- Neurology: Alzheimer's, Parkinson's, Depression
- Cardiology: Heart failure, Hypertension
These are scientific projects, and TwinMe kit data contributes directly to them.
Validation par l'industrie
Validation par l'industrie
Les leaders mondiaux investissent dans la technologie des jumeaux virtuels en tant qu'infrastructure fondamentale pour la santé de précision.
Dassault Systèmes
« Il y aura un avant et un après le jumeau virtuel du corps humain. »
Le projet Living Heart et l'initiative Emma Twin font progresser la technologie du jumeau virtuel pour les soins cardiaques et la médecine personnalisée.
Nvidia
Jumeaux virtuels de santé alimentés par la simulation IA
Les plateformes santé de NVIDIA soutiennent la simulation médicale accélérée et les infrastructures évolutives de jumeaux virtuels.
Twin Health
Jumeau numérique du corps entier pour la santé métabolique
A publié des résultats cliniques évalués par des pairs démontrant une amélioration métabolique mesurable grâce à la modélisation par jumeau.
Pourquoi c'est important : L'investissement des leaders mondiaux confirme que l'infrastructure des jumeaux virtuels devient une couche fondamentale de la santé de précision et préventive.
Join our mission
We are building the definitive biological dataset for preventive medicine. To access our data room, clinical results, or speak with leadership, reach out today.
Contact Investor Relations